In several NSCLC cells, the mRNA expression of CD80/CD86 was detected in normal tissues, risking autoimmunity reactions; hence, new strategies are encouraged to overcome this risk by using CD80/CD86 CAR-T cells and enhancing its selectivity (Wroblewski et al., 2001; Egen et al., 2002). This evidence concerns the gene CD80 and non-small cell lung carcinoma.